Post Profile






Vanderbilt, Bayer Collaborate To Develop New Therapies Against Kidney Diseases

Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.
read more

share

Related Posts


VUMC to study potential approach to reverse precancerous stomach lesions

Health : EurekAlert: Health

(Vanderbilt University Medical Center) Vanderbilt University Medical Center (VUMC) cancer researcher James Goldenring, M.D., Ph.D., has received a two-year, $200,000 grant from the DeGregorio Family Foundation in Pleasantville, New ...

Scientists create unique disease 'catalog' linked to immune system gene variations

Health : EurekAlert: Health

(Vanderbilt University Medical Center) A study led by researchers at Vanderbilt University Medical Center (VUMC) and the University of Arizona College of Pharmacy has generated the first comprehensive catalog of diseases associated ...

IU Researchers Identify Promising Treatment Option for People Suffering From Aggression After Traumatic Brain Injury

Health : Newswise Medical News

A drug originally developed in the 1960s as an antiviral medication is showing promise as a treatment option for people who suffer from increased feelings of aggression following traumatic brain injury, Indiana University School of ...

Vanderbilt University Medical Center Receives NIH Grant to Develop Artificial Kidney

Health : Newswise Medical News

The National Institutes of Health has awarded a four-year, $6 million grant to investigators at Vanderbilt University Medical Center (VUMC) and the University of California at San Francisco (UCSF) to develop an implantable artificia...

VUMC and Celgene Corporation Enter Into Strategic Research Agreement to Accelerate Development of Next-Generation Therapies

Health : Newswise Medical News

Vanderbilt University Medical Center has entered into a strategic research agreement with Celgene Corporation, a biopharmaceutical company based in Summit, New Jersey.

Comments


Copyright © 2016 Regator, LLC